In topline results from the phase 3 RELIANCE III trial, a novel NMDAR antagonist was no better than placebo as monotherapy for major depression ― despite showing earlier promise as add-on therapy.
The US Food and Drug Administration says it is in frequent contact with all manufacturers to monitor the supply of Adderall, which is approved for treating ADHD, and to help resolve this shortage.
Difficulty discerning letters or numbers at a given distance is associated with both depressive symptoms and deterioration in certain brain structures, new research suggests.